Delcath Systems Inc
DCTH
Get informed when a big investor buys or sells
+ FollowMarket Cap$421.85M
Close$
$1.07
91.9% downside
Current Fair Value
91.9% downsideOvervalued by 91.9% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $421.85 Million |
|---|---|
| Enterprise Value | $381.45 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.05 |
| Beta | 0.49 |
| Outstanding Shares | 36,021,210 |
Return
| Return on Equity | 0.50% |
|---|---|
| Return on Assets | 0.45% |
| Return on Invested Capital | 0.53% |
Valuation & Multiples
| P/E Ratio | 763.75 |
|---|---|
| PEG | -381.7 |
| Price to Sales | 13.14 |
| Price to Book Ratio | 4.38 |
| Enterprise Value to Revenue | 8.53 |
| Enterprise Value to EBIT | 626.35 |
| Enterprise Value to Net Income | 679 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0.01 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 14, 2026
EPS Estimate
$-0.10
Average shareholder expectationRevenue Estimate
$23.51 M
Average shareholder expectationNext Earnings Call
Expected Date
August 5, 2026
EPS Estimate
$-0.09
Average shareholder expectationRevenue Estimate
$26.26 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0000▼ 87.55% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 1.42%▼ 44.13% |
|---|---|
| Total Invested | $6.45M▼ 95.75% |
| Investors Holding | 22▼ 107.00% |
ESG Score
No data
About Delcath Systems Inc
CEO: Jennifer Simpson Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. Our investigational product, HEPZATO KIT™ (melphalan hydrochloride for injection/hepatic delivery system), is d...